Results from an open-label study at the Assistance Publique-Hôpitaux de Paris evaluating Roche’s (OTCQX:RHHBY -0.6%)
arthritis med Actemra (tocilizumab) in hospitalized
moderately-to-severely ill patients with COVID-19 pneumonia showed a
treatment benefit.
65 patients received tocilizumab +
standard-of-care (SOC) treatment while 64 received SOC. The primary
objective was met demonstrating a significantly lower proportion of
patients in the tocilizumab arm who died or required ventilation
compared to the SOC arm.
Results will be submitted for publication.
Tocilizumab is an interleukin-6 (IL-6) receptor antagonist. IL-6 is a pro-inflammatory protein (cytokine).
https://seekingalpha.com/news/3564645-roches-actemra-scores-early-win-in-covidminus-19-study-in-france
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.